Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CLOZAPINE VERSUS PLACEBO IN HUNTINGTONS-DISEASE - A DOUBLE-BLIND RANDOMIZED COMPARATIVE-STUDY
Autore:
VANVUGT JPP; SIESLING S; VERGEER M; VANDERVELDE EA; ROOS RAC;
Indirizzi:
LEIDEN UNIV,MED CTR,DEPT NEUROL,K5Q 112,POB 9600 NL-2300 RC LEIDEN NETHERLANDS LEIDEN UNIV,MED CTR,DEPT NEUROL,K5Q 112 NL-2300 RC LEIDEN NETHERLANDS LEIDEN UNIV,MED CTR,DEPT MED STAT NL-2300 RC LEIDEN NETHERLANDS
Titolo Testata:
Journal of Neurology, Neurosurgery and Psychiatry
fascicolo: 1, volume: 63, anno: 1997,
pagine: 35 - 39
SICI:
0022-3050(1997)63:1<35:CVPIH->2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
NEUROLEPTIC TREATMENT; BASAL GANGLIA; CHOREA; RESISTANT; DISORDERS; MOVEMENT; RIGIDITY; THERAPY; NEURONS; TRIAL;
Keywords:
HUNTINGTONS DISEASE; NEUROLEPTIC TREATMENT; CLOZAPINE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
30
Recensione:
Indirizzi per estratti:
Citazione:
J.P.P. Vanvugt et al., "CLOZAPINE VERSUS PLACEBO IN HUNTINGTONS-DISEASE - A DOUBLE-BLIND RANDOMIZED COMPARATIVE-STUDY", Journal of Neurology, Neurosurgery and Psychiatry, 63(1), 1997, pp. 35-39

Abstract

Objectives-To establish the effect of the atypical neuroleptic clozapine on chorea, voluntary motor performance, and functional disability in patients with Huntington's disease. Methods-Thirty three patients with Huntington's disease participated in a double blind randomised trial. A maximum of 150 mg/day clozapine or placebo equivalent was given for a period of 31 days. Assessments were performed in the week beforeand at the last day of the trial. Chorea was scored using the abnormal involuntary movement scale (AIMS), the chorea score of the unified Huntington's disease rating scale (UHDRS), and judgement of video recordings. Voluntary motor performance was assessed using the UHDRS motor scale. Patients and their partners completed a questionnaire regardingfunctional disability, Twelve patients already used other neurolepticmedication, which was kept unchanged during the trial period. Resultsof neuroleptic naive and neuroleptic treated patients were analysed separately. Results-Clozapine tended to reduce chorea in neuroleptic naive patients only (AIMS); improvement seemed more pronounced in patients receiving higher doses of clozapine. Other measures of chorea (UHDRS chorea score, video ratings) showed no improvement. Clozapine had nobeneficial effect on chorea in patients already receiving neurolepticmedication. Voluntary motor performance did not improve with clozapine. Neuroleptic naive patients reported aggravation of functional disability, possibly reflecting the frequent occurrence of side effects. Adverse reactions forced trial termination in six patients and dose reduction in another eight, and consisted mainly of drowsiness, fatigue, anticholinergic symptoms, and walking difficulties. Conclusions-Clozapine has little beneficial effect in patients with Huntington's disease,although individual patients may tolerate doses high enough to reducechorea. Because adverse reactions are often encountered, clozapine should be used with restraint in this patient group.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/10/20 alle ore 04:36:22